SCHEMBL2017685

SCHEMBL2017685

Brc1cccc(-c2cccnc2)n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 4/20 0.62
ALDH1A1 P00352 3/20 0.52
CYP1A2 P05177 2/20 0.52
CYP3A4 P08684 2/20 0.52
HSP90AA1 P07900 1/20 0.51
HSP90AB1 P08238 1/20 0.51
PTK2 Q05397 1/20 0.51
CYP19A1 P11511 5/20 0.50
METAP2 P50579 1/20 0.50
SIRT3 Q9NTG7 1/20 0.50
AXL P30530 1/20 0.47
PBRM1 Q86U86 1/20 0.47
MKNK1 Q9BUB5 1/20 0.47
MKNK2 Q9HBH9 1/20 0.47
MAPT P10636 2/20 0.46
CYP11B1 P15538 2/20 0.46
CYP11B2 P19099 2/20 0.46
ALK Q9UM73 1/20 0.46
CYP17A1 P05093 1/20 0.46
KARS1 Q15046 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23843626 0.92 CYP19A1 (0.60) CYP2A6ALDH1A1CYP1A2CYP3A4HSP90AA1
SCHEMBL3194702 0.86 CYP2A6 (0.74) CYP2A6ALDH1A1CYP1A2CYP3A4HSP90AA1
SCHEMBL2732828 0.83 CYP2C9 (0.50) CYP2A6ALDH1A1CYP1A2CYP3A4CYP19A1
SCHEMBL19556523 0.81 CYP2A6 (0.52) CYP2A6ALDH1A1CYP1A2CYP3A4HSP90AA1
SCHEMBL18905222 0.80 CYP19A1 (0.69) CYP2A6ALDH1A1CYP1A2CYP3A4HSP90AA1
SCHEMBL12925581 0.80 CYP2A6 (0.67) CYP2A6ALDH1A1CYP1A2CYP3A4HSP90AA1
SCHEMBL2462787 0.80 CHRNB2 (0.69) ALDH1A1MAPTKDM4ETP53HPGD
SCHEMBL12279610 0.80 USP8 (0.47) CYP2A6ALDH1A1CYP1A2CYP3A4CYP19A1
SCHEMBL2225949 0.78 HPGDS (0.53) CYP2A6ALDH1A1CYP19A1AXLPBRM1
SCHEMBL10031168 0.78 CYP2A6 (0.65) CYP2A6ALDH1A1CYP1A2CYP3A4HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10892423-B2 Condensed cyclic compound and organic light-emitting device including the same SAMSUNG DISPLAY CO., LTD. (KR) 2021-01-12 US disclosed
US-10038146-B2 Organic light-emitting compound and organic electroluminescent device using same DOOSAN CORPORATION (KR) 2018-07-31 US disclosed
US-10038146-B2 Organic light-emitting compound and organic electroluminescent device using same DOOSAN CORPORATION (KR) 2018-07-31 US disclosed
US-20180159050-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2018-06-07 US disclosed
US-9761813-B2 Organic light-emitting compound and organic electroluminescent device using same DOOSAN CORPORATION (KR) 2017-09-12 US disclosed
US-9761813-B2 Organic light-emitting compound and organic electroluminescent device using same DOOSAN CORPORATION (KR) 2017-09-12 US disclosed
US-9761813-B2 Organic light-emitting compound and organic electroluminescent device using same DOOSAN CORPORATION (KR) 2017-09-12 US disclosed
CN-104379572-B Benzo [a] carbazole compound, electron transport materials and use its organic electric-field light-emitting element 捷恩智株式会社 2016-09-21 CN disclosed
WO-2015111943-A1 ORGANIC COMPOUND, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING SAME 주식회사 두산 2015-07-30 WO disclosed
WO-2015111943-A1 ORGANIC COMPOUND, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING SAME 주식회사 두산 2015-07-30 WO disclosed
US-7030128-B2 Central nervous system disorders; anxiolytic agents; anticonvulsants; cognition activators; side effect reduction MERCK SHARP & DOHME LTD. (GB) 2006-04-18 US disclosed
US-20060014742-A1 Amide derivative NIPPON SHINYAKU CO., LTD. (JP) 2006-01-19 US disclosed
CN-1678590-A Amide derivative and pharmaceutical NIPPON SHINYAKU CO LTD (JP) 2005-10-05 CN disclosed
EP-1533304-A1 AMIDE DERIVATIVE Nippon Shinyaku Co., Ltd. (JP) 2005-05-25 EP disclosed
US-20050004125-A1 Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) JANSSEN PHARMACEUTICA N.V. (BE) 2005-01-06 US disclosed
EP-1448556-A1 HETEROARYL AMINES AS GLYCOGEN SYNTHASE KINASE 3BETA INHIBITORS (GSK3 INHIBITORS) JANSSEN PHARMACEUTICA N.V. (BE) 2004-08-25 EP disclosed
US-20040092533-A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors MERCK SHARP & DOHME LTD. (GB) 2004-05-13 US disclosed
EP-1383768-A1 IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LTD. (GB) 2004-01-28 EP disclosed
WO-2003037891-A1 HETEROARYL AMINES AS GLYCOGEN SYNTHASE KINASE 3BETA INHIBITORS (GSK3 INHIBITORS) JANSSEN PHARMACEUTICA N.V. (BE) 2003-05-08 WO disclosed
WO-2002076983-A1 IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2002-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10038146-B2 Organic light-emitting compound and organic electroluminescent device using same IDO1, IDO2, KYNU CYP2A6 2126/4885ALDH1A1 458/4885CYP1A2 737/4885
US-20060014742-A1 Amide derivative ABL1, ABL2, BCR CYP2A6 239/4885ALDH1A1 753/4885CYP1A2 252/4885
US-20040092533-A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors GABRA3, GABRA1, GABRA4 CYP2A6 425/4885ALDH1A1 495/4885CYP1A2 594/4885
US-20180159050-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME CRY1, CCNE2, CCNT1 CYP2A6 3284/4885ALDH1A1 127/4885CYP1A2 1512/4885
US-10892423-B2 Condensed cyclic compound and organic light-emitting device including the same CRY1, CCNE2, CCNT1 CYP2A6 3284/4885ALDH1A1 127/4885CYP1A2 1512/4885
US-20050004125-A1 Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) GSK3B, GSK3A, GSKIP CYP2A6 1915/4885ALDH1A1 3842/4885CYP1A2 1024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.